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ABSTRACT. The gene XRCC3 (X-ray cross complementing group 3) 
has the task of repairing damage that occurs when there is recombination 
between homologous chromosomes. Repair of recombination between 
homologous chromosomes plays an important role in maintaining 
genome integrity, although it is known that double-strand breaks are 
the main inducers of chromosomal aberrations. Changes in the XRCC3 
protein lead to an increase in errors in chromosome segregation due to 
defects in centrosomes, resulting in aneuploidy and other chromosomal 
aberrations, such as small increases in telomeres. We examined XRCC3 
Thr241Met polymorphism using PCR-RFLP in 80 astrocytoma and 
glioblastoma samples. The individuals of the control group (N = 100) 
were selected from the general population of the São Paulo State. 
Odds ratio and 95%CI were calculated using a logistic regression 
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model. Patients who had the allele Met of the XRCC3 Thr241Met 
polymorphism had a significantly increased risk of tumor development 
(odds ratio = 3.13; 95% confidence interval = 1.50-6.50). There were 
no significant differences in overall survival of patients. We suggest 
that XRCC3 Thr241Met polymorphism is involved in susceptibility for 
developing astrocytomas and glioblastomas.
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INTRODUCTION
Tumors of the central nervous system (CNS) represent approximately 2% of all can-
cers, with an estimated 4.2 to 5.4 per 100,000 individuals per year (Ohgaki and Kleihues, 
2005). Although the incidence of CNS tumors is small compared with other cancers, these 
are among the most serious human malignancies, since they affect coordination and integra-
tion of all organic activities. Moreover, as each region of the brain has a vital function, the 
therapy used in other cancers (total surgical removal of the organ or tumor with a generous 
margin of normal tissue) cannot be applied to cure brain tumors (Louis et al., 2002; Ohgaki 
and Kleihues, 2005). Gliomas are the most common tumors of the CNS. Despite the remark-
able progress in the characterization of the molecular pathogenesis of gliomas, these tumors 
remain incurable and, in most cases, refractory to treatment due to their molecular heterogene-
ity (Kleihues et al., 2002).
Astrocytomas account for the large majority of gliomas, making up 70% of the total, 
and can be divided into: pilocytic astrocytomas (grade I), including low-grade astrocytomas 
(grade II), anaplastic (grade III) and glioblastoma (grade IV) (Kleihues et al., 2002). The 
relevance of the graduated scheme of malignancy based on histopathology is indicated by 
patient survival. Patients with low-grade astrocytomas (grade II) have a median survival of 
about seven years, patients with anaplastic astrocytomas (grade III) have a mean survival of 
half of that time (McCormack et al., 1992), while patients with glioblastoma have in average 
9 to 11 months (Simpson et al., 1993). Unlike grade I astrocytomas, the progression of tumors 
of grades II and III for most malignant tumors is well documented (Ino et al., 2001; Col-
lins, 2004; Hartmann et al., 2004; Ichimura et al., 2004; Ohgaki, 2005). Ng and Lam (1998) 
suggested that glioblastomas should be divided into two clinically and molecularly distinct 
entities: primary glioblastomas or new ones, that occur in elderly patients and are clinically 
very aggressive, and secondary glioblastomas, which develop from preexisting low-degree 
astrocytomas and have a more prolonged clinical course.
The XRCC3 (X-ray cross complementing group 3) gene is needed to repair damage 
caused when recombination occurs between homologous chromosomes (Loizidou et al., 2008; 
Andreassi et al., 2009). The repair of recombination between homologous chromosomes is a 
mechanism that fixes various types of DNA damage. The large number of repeated sequences 
can potentially lead to a large number of undesirable interactions between chromosomes. The 
repair of recombination between homologues plays an important role in maintaining genome 
integrity. Although it is known that double-strand breaks are the main inducers of chromo-
somal aberrations, the mechanisms by which these are formed are still unresolved (Griffin and 
Tracker, 2004).
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Deficiencies in the XRCC3 protein lead to an increase in errors in chromosome 
segregation due to defects in centrosomes, resulting in aneuploidy and other chromosomal 
aberrations such as small increases in telomeres (Thacher, 2005). XRCC3 is an important 
component in the repair machinery via homologous recombination. Changes in this machine 
due to the presence of polymorphisms lead to damage that results in tumor development 
(Jiao et al., 2008).
The XRCC3 gene is mapped to 14q32.2 (Tebbs et al., 1995; Zou et al., 2009). The 
XRCC3 Thr241Met polymorphism (rs861539) located in exon 7 is characterized by the 
substitution of thymine (T) to cytosine (C) at codon 241, leading to a change of threonine 
(Thr) to methionine (Met), and could affect enzyme function and/or its interaction with 
other proteins involved in repair of DNA damage (Matullo et al., 2001; Jiao et al., 2008; 
Andreassi et al., 2009).
In the present research, a case-control study was conducted to examine the genotype 
distribution of Thr241Met SNP and to search for an association between astrocytomas and 
glioblastomas and XRCC3 SNP, using the polymerase chain reaction-restriction fragment 
length polymorphism (PCR-RFLP) approach.
MATERIAL AND METHODS
Study population
Eighty gliomas were analyzed, which had been surgically resected from previously 
untreated patients under the care of the Neurosurgery Department of Fundação Pio XII, Can-
cer Hospital of Barretos (Barretos, SP, Brazil). The samples, classified according to WHO 
criteria, were: 43 astrocytomas and 37 glioblastomas. The clinical outcome, including length 
of survival, was obtained from patient records. For SNP studies, blood samples from 100 
healthy individuals were collected as control. Because of the highly heterogeneous ethnic 
composition of the Brazilian population, the individuals of the control group were selected 
from the general population of São Paulo State, with no family history of cancer in first-
degree relatives.
DNA extraction and primer construction
DNA extraction was performed using proteinase K and phenol-chloroform accord-
ing to routine molecular biology protocols. Primers were constructed using the Gene Runner 
3.05 program (Hasting Software, Inc.) from the gene sequence of the XRCC3 Thr241Met 
polymorphism, obtained in the dbSNP of NCBI (accession No. rs861539). Table 1 shows the 
primers and PCR product sizes.
SNP XRCC3 Thr241Met Primers Sequence (5'-3') Length (bp) PCR product (bp)
 Thr241MetF GCT GTC TCG GGG CAT GGC TC 20 235
 Thr241MetR GCT TCC GCA TCC TGG CTA AA 20
PCR = polymerase chain reaction; SNP = single nucleotide polymorphism.
Table 1. Polymerase chain reaction primers.
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PCR was carried out in a final volume of 25 μL containing 50 ng genomic DNA tem-
plate, 1X PCR buffer with 2 mM MgCl2, 0.4 μM of each primer (Invitrogen), 50 μM dNTPs 
(Amersham Biosciences) and 0.5 U DNA polymerase (Biotools). The PCR cycling conditions 
were: 94°C for 5 min, followed by 35 denaturation cycles of 30 s at 94°C, 30 s of annealing at 
56°C, and 30 s of extension at 72°C, and a final elongation cycle at 72°C for 5 min. For RFLP, 
the PCR products were digested by Hsp92II (1 U at 37°C for 16 h - Thr241Met). Hsp92II 
recognizes a restriction site at Met241 (CATG/NN) and generates two fragments of different 
sizes (125 and 110 bp), while Thr241 allele generates only one fragment of 235 bp. DNA frag-
ments were electrophoresed through a 10% acrylamide:bisacrylamide gel (19:1) and stained 
with silver nitrate.
Statistical analysis
PCR-RFLP - The independence of alleles (Hardy-Weinberg equilibrium) was ensured 
using the chi-square test. The distribution of genotype and allele frequencies among patients 
and controls was compared using chi-square and Fisher exact tests. Overall survival curves 
were obtained using the Kaplan-Meier method and compared with the log-rank test. Odds ra-
tio (OR) and 95% confidence intervals (CI) were calculated using a logistic regression model. 
Statistical significance was set at P < 0.05. Statistical analyses were performed with GraphPad 
InStat 4.0 and GraphPad Prism 5.0 software programs (GraphPad Software, Inc.).
RESULTS
Analysis of tumors and control populations according to XRCC3 Thr241Met
Eighty patients and 100 control subjects were included in this study. The patient sam-
ple comprised 28 females and 52 males (M/F ratio = 0.65) and the control sample consisted 
of 63 males and 37 females (M/F ratio = 1.7). Average age in the patient group was 45 years 
(range = 1-75) and in the control group it was 45 years (range = 18-72). Genotype frequencies 
in controls and patients were in Hardy-Weinberg equilibrium. Allele and genotype frequencies 
of XRCC3 Thr241Met in controls and patients are shown in Table 2. The frequencies of Thr/
Thr, Thr/Met and Met/Met among patients were 66.3, 22.5 and 11.3%, while for the controls 
the frequencies of Thr/Thr, Thr/Met and Met/Me were 86.0, 9.0 and 5.0%, respectively (P = 
0.007). The Met241 allele frequency was statistically significant between cases and controls 
(0.22 and 0.09, respectively; P = 0.001).
SNP XRCC3 Thr241Met Genotype Case group Control group P
 Thr/Thr 53 (66.3%) 86 (86.0%) 0.007
 Thr/Met 18 (22.5%) 9 (9.0%)
 Met/Met   9 (11.3%) 5 (5.0%)
 Met 241 allele frequency 0.22 0.09 0.001
Data are reported as number with percent in parentheses. SNP = single nucleotide polymorphism.
Table 2. Allele and genotype frequencies in case and control groups.
Logistic regression analysis for the investigation of polymorphism association with 
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risk of astrocytomas and glioblastomas is presented in Table 3. Compared to Thr/Thr, the 
most common genotype of the polymorphism XRCC3 Thr241Met in the study population, the 
genotypes with the presence of the allele Met revealed an increased risk of tumor development 
(OR = 3.13; 95% CI = 1.50-6.50; P = 0.002).
SNP XRCC3 Thr241Met Genotype Case/Control OR (95%CI) P
 Thr/Thr 53/86 1 ־
 Thr/Met 18/9 3.24 (1.36-7.75) 0.006
 Met/Met 9/5 2.92 (0.93-9.18) 0.057
 Thr/Met; Met/Met 27/14 3.13 (1.50-6.50) 0.002
SNP = single nucleotide polymorphism; OR = odds ratio; 95%CI = 95% confidence interval.
Table 3. Association of XRCC3 Thr241Met single nucleotide polymorphisms with risk of cancer.
Comparison of overall survival of patients according to the XRCC3 Thr241Met geno-
type did not show significant differences (P = 0.862). In the XRCC3 Thr241Metl genotype, the 
median survival of patients with Thr/Met and Met/Met was 61 weeks (Figure 1).
Figure 1. Overall survival in patients according to the XRCC3 Thr241Met single nucleotide polymorphism.
DISCUSSION
SNPs are recognized as important tools in human genetics and medicine and have 
been widely used in genetic association studies of various complex diseases, such as cardio-
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vascular, psychiatric and autoimmune diseases, obesity, osteoporosis, diabetes, and cancer 
(Curran et al., 2001; Miller and Kwok, 2001; Lin et al., 2003; Tamura et al., 2003; Yamada et 
al., 2003; Hirai et al., 2005). In humans, several reviews of SNPs have also been conducted 
throughout the genome, with the intention of determining the patterns of the haplotypes in 
the populations (Daly et al., 2001; Jeffreys et al., 2001; Patil et al., 2001; Reich et al., 2001; 
Gabriel et al., 2002). Data from these tests are extremely useful for studying the genetic basis 
of common complex diseases (Phillips et al., 2003). Polymorphisms in DNA repair genes may 
be associated with differences in the efficient repair of DNA damage and may influence the 
risk for developing tumors. This can result in subtle changes in the structure of proteins from 
genes and alter their function (Sreeja et al., 2008).
In this study, we determined the relationship between XRCC3 Thr241Met SNPs and 
susceptibility to cancer and patient survival in 80 astrocytomas and glioblastomas. Some stud-
ies have linked this variant with some types of cancer, including breast cancer (Smith et al., 
2003), lung (Jacobsen et al., 2004) and skin melanoma (Winsey et al., 2000).
The present case-control study showed that Met241 was more frequent in the cancer 
population than in non-cancer populations (0.22 and 0.09, respectively; P = 0.001), and that 
the presence of this genotype may increase the risk of developing astrocytomas and glioblas-
tomas (OR = 3.13; 95%CI = 1.50-6.50; P = 0.002).
Lee et al. (2007) in a meta-analysis on Thr241Met reported that Met241 is associated 
with risk of developing breast cancer in Asian and Caucasian populations. The Thr241Met 
substitution is the most thoroughly investigated polymorphism in XRCC3 due to the C>T 
transition at exon 7. Functional data also suggest that the polymorphism may be associated 
with slightly decreased DNA repair capacity (Jara et al., 2010).
Kiuru et al. (2008) studied the XRCC3 Thr241Met polymorphism in samples of ner-
vous system tumors and concluded that the genotype Thr/Met and homozygous Met/Met are 
associated with increased risk for developing this kind of tumors.
Zhou et al. (2009) conducted a case-control study in a Chinese population on the 
XRCC3 Thr241Met polymorphism in 771 samples of gliomas and 752 control samples, con-
cluding that the presence of genotype Met/Met may contribute to the development of gliomas.
The XRCC3 Thr241Met polymorphism was analyzed in samples from breast cancer. 
The result demonstrated that the presence of the polymorphism does not interfere with disease 
development (Loizidou et al., 2008).
In summary, our study provides evidence that XRRC3 Thr241Met may contribute 
to the etiology of human astrocytomas and glioblastomas, since the allele Met241 was found 
more frequently in patients than controls, but there was no association between the genotypes 
and the patients’ survival.
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